Optimizing Maryland’s Innovation Ecosystem: A Whitepaper on Implementing a Research and Development Tax Credit Payroll Offset for Early-Stage Enterprises

1. Executive Summary: The Liquidity Crisis in Maryland’s Innovation Corridor

Maryland has long positioned itself as a premier destination for high-technology industries, particularly within the life sciences, cybersecurity, and quantum computing sectors. With a workforce of approximately 52,000 life sciences workers and an average industry wage of $142,243—which is 94% higher than the state’s private-sector average—Maryland’s economic health is fundamentally intertwined with the success of its innovation-led businesses.¹ Central to this success is the Maryland Research and Development (R&D) Tax Credit, administered under Tax-General Article § 10-721, which provides a fiscal incentive for companies to increase their year-over-year research expenditures within the state.² However, as the global competition for high-tech capital intensifies, significant gaps in the state’s incentive framework have emerged, threatening Maryland’s status as a top-tier innovation hub.

The primary policy issue addressed in this report is the lack of a payroll tax offset option within the Maryland R&D credit framework. Unlike the federal “pathway” established by the Protecting Americans from Tax Hikes (PATH) Act of 2015 and expanded by the Inflation Reduction Act of 2022, which allows qualified small businesses to apply R&D credits against their employer-side payroll tax liabilities, Maryland’s credit remains primarily an income tax credit.³ While the Maryland credit is refundable for companies meeting a strict “small business” definition—defined as having net book value assets of less than $5 million—this threshold inadvertently excludes a critical segment of the state’s startup ecosystem.⁶

For pre-revenue biotechnology and deep-tech firms, capital is frequently tied up in specialized lab equipment, intellectual property, and essential infrastructure, which often causes their net book value assets to exceed the $5 million limit long before they achieve profitability or even generate their first dollar of revenue.⁷ Consequently, these firms are left with non-refundable income tax credits that they cannot utilize, effectively stranding the incentive during the most cash-constrained years of their development lifecycle. This report analyzes the mechanics of the current framework, compares it to successful models in other jurisdictions, and proposes legislative solutions to integrate a payroll tax offset, thereby ensuring that Maryland remains a competitive and resilient hub for global innovation.

2. The Evolution and Mechanics of the Maryland Research and Development Tax Credit

The Maryland Research and Development Tax Credit was established in 2000 to stimulate private-sector investment in technological advancement and to foster a robust ecosystem for the commercialization of new products and processes.¹⁰ For over two decades, the program operated under a dual-credit structure consisting of a Basic Credit and a Growth Credit.¹⁰ The Basic Credit offered a 3% incentive for R&D expenses up to a company’s four-year historical average (the base amount), while the Growth Credit provided a 10% incentive for expenses exceeding that baseline.⁹

This dual structure was intended to reward both consistent research activity and rapid expansion. However, the legislative journey of the credit has been marked by frequent adjustments to its aggregate caps and eligibility rules. In 2021, the General Assembly enacted Senate Bill 196, which simplified the program by repealing the Basic Credit entirely and consolidating all funding into an expanded Growth Credit, raising the total aggregate cap to $12 million annually.¹⁰ The current framework provides a tax credit equal to 10% of the Maryland qualified research and development expenses (QREs) incurred during the taxable year that exceed the Maryland base amount.⁶

Administrative Coordination and Certification Requirements

The administration of the R&D credit involves a unique dual-agency coordination between the Maryland Department of Commerce and the Maryland Comptroller’s Office.² This process is not a passive deduction; rather, it requires proactive certification from the Department of Commerce before a taxpayer can claim the credit on a return.² The Department of Commerce acts as the primary administrative authority for certifying eligibility and allocating the state’s credits under Tax-General Article § 10-721.²

Table 1: Maryland R&D Credit Administrative Framework

The “Maryland Base Amount” is a critical component of the calculation, intended to ensure that the credit incentivizes incremental growth rather than routine spending. It is calculated by taking the “Maryland Base Percentage”—the ratio of Maryland QREs to Maryland gross receipts for the preceding four years—and multiplying it by the average Maryland gross receipts for those same years.² For startups in their first year of R&D, the base amount is typically zero, allowing the full 10% credit on all qualifying expenditures in the initial year.⁷ However, the $12 million annual cap necessitates a mandatory pro-rata reduction when the aggregate value of qualifying applications exceeds the state’s budget.¹⁰ In practice, the $12 million cap is routinely oversubscribed, meaning the effective credit rate is often significantly lower than the statutory 10%.⁷

3. Identifying the Policy Gap: The Asset-Test Barrier and the Liquidity Crunch

The central deficiency in the current Maryland framework lies in its binary and restrictive treatment of small businesses for the purpose of credit refundability. Under current law, the R&D credit is only refundable for a “small business,” defined as a for-profit entity with net book value assets totaling less than $5 million at either the beginning or the end of the taxable year for which the expenses were incurred.⁶ If a business exceeds this $5 million threshold, any certified credit that exceeds the company’s income tax liability must be carried forward to future tax years for up to seven years.⁶

The Perverse Incentives of the Net Book Value Definition

The definition of “net book value assets” used by the Department of Commerce includes the total value of a business’s assets, including intangibles, minus depreciation and amortization, but notably does not exclude liabilities.⁶ This specific accounting treatment creates a significant “incentive trap” for high-capital-intensity startups, particularly those in the life sciences and advanced manufacturing sectors.⁷

Table 2: Impact of the Asset Test on Startups

A pre-revenue biotechnology firm may successfully raise $10 million in venture capital to fund a multi-year clinical trial. Even if the firm has zero revenue and carries $5 million in debt, the cash on the balance sheet alone would disqualify them from “small business” status under Maryland’s current definition.⁶ Consequently, if that firm conducts $2 million of R&D in Maryland, they would receive a non-refundable credit (subject to proration) that can only be used to offset Maryland income tax.¹⁰ Since the firm is pre-revenue and pre-profit, they have no income tax liability, and the credit must be carried forward.⁶ In an industry where the path to commercialization often exceeds ten years, a seven-year carryforward period may expire before the company ever generates sufficient profit to utilize the credit.¹³

The Problem of Stranded Capital in a High-Growth Sector

This “stranded” nature of tax credits represents a massive opportunity cost for Maryland-based startups. While the federal government has recognized this issue and allows these same companies to use R&D credits to offset payroll taxes, Maryland’s refusal to offer a similar pathway creates a liquidity gap that can stifle growth.³ This gap is particularly acute given that wages—the primary component of qualified research expenses—are subject to immediate state withholding taxes.⁷

The current system essentially requires a pre-revenue startup to pay Maryland withholding taxes on the very research and development labor that the state is ostensibly trying to incentivize, while the incentive itself remains locked in a non-refundable income tax credit that cannot be accessed for years.⁵ This lack of liquidity forces founders to seek additional dilutive venture capital just to cover state tax obligations, effectively taxing the very innovation the state claims to support.⁵

4. The Federal Benchmark: IRC Section 41(h) and the PATH Act Evolution

The modern gold standard for innovation-led tax incentives is the federal Research Credit payroll tax offset, codified in Internal Revenue Code (IRC) § 41(h). Originally enacted as part of the Protecting Americans from Tax Hikes (PATH) Act of 2015, this provision was designed specifically to assist early-stage companies that invest heavily in research but lack the income tax liability to benefit from traditional credits.³

Federal Eligibility: A Revenue-Based Approach

To qualify as a “qualified small business” (QSB) for the federal payroll offset, a company must meet criteria that are significantly more flexible and revenue-focused than Maryland’s asset-based test. The federal government recognizes that the size of a company’s research effort is better measured by its stage of commercialization than by its balance sheet assets.³

• Gross Receipts Threshold: The business must have less than $5 million in gross receipts for the current taxable year.³
• Age of Revenue: The business must have had no gross receipts for any taxable year preceding the five-taxable-year period ending with the current year.³

Table 3: State vs. Federal Small Business Definitions

Under the federal system, a QSB can elect to apply up to $500,000 per year of its R&D credit toward the employer portion of Social Security and Medicare taxes.⁴ This provides immediate cash flow benefits, as the offset applies to taxes that must be paid every quarter, regardless of the company’s profitability.³ If the elected credit exceeds the payroll tax for a given quarter, the excess is carried forward to the next quarter.³ This mechanism ensures that the incentive is “monetized” almost immediately, providing the company with non-dilutive capital to reinvest in further research or hiring.³

5. Comparative Analysis of State-Level R&D Monetization Models

Maryland’s neighboring and competitor states have already recognized the necessity of bridging the liquidity gap for pre-revenue startups. Two notable models provide a roadmap for how Maryland could modernize its own program: the Georgia payroll withholding offset and the New Jersey technology tax certificate transfer program.

Georgia: The Direct Payroll Withholding Offset Model

Georgia offers an R&D tax credit that mirrors the federal four-part test but includes a crucial monetization feature for the “innovation” industries.²¹ After a company uses the credit to offset up to 50% of its Georgia corporate income tax liability, any remaining unused credit can be applied against the company’s state payroll withholding liability.²²

The Georgia model is particularly efficient because it uses the state’s existing withholding tax system to deliver the benefit.²² Companies file a specific notice of intent (Form IT-WH) within 30 days of filing their income tax return to elect the payroll offset.²³ The Georgia Department of Revenue then has 120 days to review and approve the amount, which the company then uses to reduce its future monthly or quarterly withholding payments.²³ This provides a direct cash-flow benefit without requiring the state to issue a direct refund check, as the company simply retains the cash it would have otherwise remitted to the state on behalf of its employees.²²

New Jersey: The Tax Certificate Transfer (NOL) Program

New Jersey takes a different approach by allowing unprofitable technology and biotechnology companies to sell their unused R&D tax credits and Net Operating Losses (NOLs) to other corporate taxpayers in exchange for cash.²⁴ This program, managed by the New Jersey Economic Development Authority (NJEDA), allows firms with fewer than 225 U.S. employees to turn their credits into capital for equipment, facilities, or further research.²⁵

Table 4: New Jersey Transfer Program Mechanics

The New Jersey model essentially creates a private secondary market for tax credits, where established, profitable corporations act as the “buyers” to lower their own tax bills, while startups receive immediate working capital.²⁴ This program has been highly successful in sustaining New Jersey’s life sciences cluster, with approximately $30 million in credits disbursed through the program in 2024 alone.²⁶

6. Proposed Solution 1: Implementing a Maryland Payroll Withholding Offset

The most practical and administratively feasible solution for the Maryland General Assembly is the creation of a payroll withholding offset mechanism modeled after the federal § 41(h) and the Georgia system. This would allow pre-revenue and early-stage firms that are currently ineligible for the small business refund due to the $5 million asset test to nonetheless monetize their R&D credits.

Leveraging Existing Frameworks: Administrative Release No. 34

Maryland already has an established administrative framework for applying certain tax credits against employer withholding. Under Administrative Release No. 34, the Comptroller’s Office allows tax-exempt 501(c)(3) and (c)(4) organizations to apply credits such as the “Employment Opportunity” and “Qualifying Employees with Disabilities” credits against the income tax they are required to withhold from employee wages.²⁷

The proposed reform would extend this privilege to for-profit companies that have been certified for the R&D Tax Credit by the Department of Commerce but lack the income tax liability to utilize it.

Proposed Workflow for a Maryland Payroll Offset:

1. Department of Commerce Certification: The company applies for the R&D credit by November 15, as per current law.⁶ The Department of Commerce verifies the QREs and issues a certification letter by February 15.⁶
2. Election on Income Tax Return: Upon receiving certification, the company makes an irrevocable election on its Maryland income tax return (Form 500 or Form 510) to treat a portion of the credit as a payroll withholding credit.⁴
3. Application to Form MW508: The credit is applied to the Annual Employer Withholding Reconciliation Return (Form MW508).²⁹
4. Real-Time Cash Flow Benefit: The company reduces its periodic (monthly or quarterly) withholding remittances (Form MW506) based on the estimated credit, with a final reconciliation performed on the MW508 at year-end.²⁷

This solution avoids the need for the state to issue large refund checks and instead allows companies to retain a portion of the cash they are already collecting from employees. Because this mechanism is already in use for non-profits via Form MW508CR, the IT infrastructure within the Comptroller’s bFile and Maryland Tax Connect systems is largely already in place.²⁹

7. Proposed Solution 2: Modernizing the “Small Business” Eligibility Definition

A secondary, complementary solution is to revise the antiquated $5 million net book value asset test. As currently constructed, this test creates a “perverse incentive” against infrastructure investment and fundraising.⁷ To align with modern economic realities and federal standards, Maryland should adopt a revenue-based or employee-based definition for small business refundability.

Alternative Criteria for a “Qualified Innovation Business”

Maryland could adopt a hybrid definition of “Qualified Small Business” that mimics the federal approach while maintaining state-specific guardrails to prevent abuse by large out-of-state entities.

Table 5: Proposed Eligibility Modernization

By shifting from an asset-based test to a revenue-based test, Maryland would ensure that biotechnology startups—which often have high balance sheet values due to specialized equipment but are years away from profit—are not excluded from the refundability provision.⁷ A company with $20 million in venture capital but $0 in revenue is still, for all intents and purposes, a fragile early-stage enterprise that requires liquidity to survive its R&D phase.⁵

The “Start-Up Pathway” Implementation

A “Start-Up Pathway” could be established within the existing R&D credit framework. Companies that fail the $5 million asset test but have less than $1 million in annual Maryland gross receipts could be granted “Conditional Refundability” or the right to the payroll tax offset. This would specifically target the “innovation gap” where high-tech firms are too large for the current small business set-aside but too small to have meaningful income tax liability.¹⁰

8. Implementation Strategy: Accountability, Fraud Prevention, and Oversight

Any expansion of tax credit monetizability must be accompanied by robust fraud prevention measures and administrative oversight to ensure that taxpayer dollars are effectively targeting genuine innovation. The Maryland Comptroller’s Office already maintains a “rigorous process” and “sophisticated data processing systems” to detect and prevent tax refund fraud.³⁴

Multi-Layered Verification and Audit Procedures

To implement the payroll offset while avoiding the risk of “bogus” claims or “ghost employees,” the state can deploy several layers of verification:

• Mandatory Pre-Certification: No company should be allowed to claim a payroll offset without first receiving a formal tax credit certificate from the Department of Commerce.² This ensures the underlying R&D activity has been verified under federal IRC § 41 standards.⁶
• Employer Withholding Reconciliation: The existing MW508 reconciliation process compares the total withholding reported by the employer with the individual W-2 statements issued to employees.³⁰ This “cross-check” ensures that a company cannot claim a payroll credit for more than it has actually paid in wages.²⁹
• Automated Match Audits: The Comptroller’s “Automated Match Audits” compare information available from the IRS with information reported on Maryland returns.³⁶ If a company claims an R&D credit in Maryland but did not report similar R&D activity or wage levels federally, a flag is triggered for a manual investigation.³⁴
• Strict Documentation Requirements: Taxpayers must be required to retain project-specific records, including innovation logs, testing protocols, and general ledgers showing supply costs for at least four years.²
• Whistleblower Program Integration: Leveraging the existing Business Tax Fraud Tips & Whistleblower Referral program, the state can incentivize the reporting of fraudulent incentive claims by offering rewards for information that leads to the recovery of misused funds.³²

Phased Administrative Rollout

To allow the Comptroller’s Office and the Department of Commerce to adjust their digital systems, the policy change could be phased in over two fiscal years.

• Phase 1: Allow companies to apply unused, certified R&D credits from the current tax year against their fourth-quarter state withholding only, simplifying the initial reconciliation.
• Phase 2: Expand to full quarterly or monthly offsetting once the automated reconciliation systems within the “Maryland Tax Connect” portal are fully integrated and tested.³⁰

9. Economic Impact and Fiscal Return on Investment (ROI)

A primary concern for the Maryland legislature is the immediate fiscal impact of making a non-refundable credit refundable or transferable through a payroll offset. However, this cost must be framed as a strategic investment in the state’s high-wage tax base rather than a mere expenditure.

The $12 Million Cap as a Built-in Fiscal Guardrail

Because the Maryland R&D Tax Credit is already subject to a strict $12 million annual cap, the implementation of a payroll offset does not necessarily increase the total amount of credits the state awards.⁶ Instead, it changes the timing and efficiency of the benefit.

Table 6: Fiscal Budgetary Impact

While the payroll offset might lead to the $12 million cap being hit more consistently, it ensures that every dollar of the incentive is actually doing the work intended: fueling active, local innovation.² Under the current system, a significant portion of the $12 million may be awarded to companies that never actually use it because they fail before reaching profitability—meaning the state is “saving” money, but at the cost of failing to support the very firms that needed the incentive to survive.

Multiplier Effects and Revenue Realization

Economic development investments in Maryland have a proven track record of high returns. According to a 2026 study by the Maryland Economic Development Association (MEDA), every $1 invested in county-level economic development generated an average of $9.18 in combined state and local tax revenue.³⁸

Specifically within the life sciences and cybersecurity sectors, the economic multiplier is even more significant. Maryland’s life sciences workers earn nearly double the private sector average.¹ These high wages result in:

• Direct PIT Revenue: Increased personal income tax (PIT) collections from the high-paying jobs created or retained by R&D-intensive firms.³⁸
• Ancillary Economic Activity: Revenue generated by the specialized vendors, contractors, and service providers that support the R&D ecosystem in regions like the I-270 corridor and Baltimore.¹⁵
• Long-Term Tax Base Expansion: Strengthening local property tax bases and creating a “pathway to quality jobs” that anchors the state’s long-term growth and resilience.³⁸

By providing a payroll offset, the state effectively trades a delayed, uncertain income tax reduction for an immediate investment in high-wage jobs. The personal income tax collected from a single $142,000 scientist would quickly repay the state for the cost of the R&D credit used to fund that scientist’s position.¹

10. The Strategic Importance of Reform and the Risks of Inaction

The global market for innovation is no longer a localized competition between states; it is a battle for the future of global technology leadership. Maryland is in direct contention with established hubs like Massachusetts and California, as well as rising competitors like North Carolina, New York, and international players like China.¹

Addressing the Threat of Innovation “Brain Drain”

Recent data indicates that while Maryland remains a top-tier biopharma region, its business formation growth has not kept pace with the national average since 2019.¹ In 2025, the industry reported that while billions in new manufacturing investments were being made across the U.S., Maryland received $0 of those specific pharmaceutical manufacturing funds.¹

Table 7: Maryland Bioscience Growth vs. National Average

If Maryland fails to modernize its R&D incentives, the consequences include:

• Scientific Brain Drain: Highly educated STEM PhDs are globally mobile. While Maryland has historically been good at retaining talent, the lack of capital for local startups can force these individuals to move to Massachusetts or California, where the ecosystem is more liquid and supportive of early-stage ventures.⁴²
• Involuntary Corporate Relocation: As companies move from the R&D phase into the clinical trial and manufacturing phases, the lack of refundable or transferable credits in Maryland may drive them to relocate to states like New Jersey or Georgia that offer better cash-flow incentives.¹⁵
• Pipeline Stagnation: Without the ability to monetize credits, early-stage firms may be forced to take on more dilutive equity financing or cut their research budgets, slowing the “velocity of innovation” and reducing the chances of a major scientific breakthrough occurring in Maryland.¹
• Erosion of National Security Leadership: International competitors, particularly China, are aggressively subsidizing their biotech sectors. China now surpasses the U.S. in total clinical drug trials, with a 26.3% year-over-year growth in its advanced modalities pipeline.¹ To remain a leader, Maryland must ensure its domestic incentives are as efficient as possible.

Conclusion: A Call for Legislative Action

The Maryland Research and Development Tax Credit is a cornerstone of the state’s economic development strategy, yet its current lack of a payroll offset mechanism limits its efficacy for the state’s most innovative and vulnerable businesses. The “innovation gap”—where pre-revenue companies with high asset values are denied the ability to monetize their credits—represents a failure of the current statutory framework to reflect the realities of modern deep-tech entrepreneurship.

To restore Maryland’s competitive edge and maximize the ROI of its $12 million annual investment in R&D, the following legislative actions are recommended for the General Assembly:

1. Establish a State Payroll Withholding Offset: Create a statutory pathway for certified R&D credit recipients to apply their credits against employer-side state withholding via the MW508 reconciliation process, mirroring the federal § 41(h) and Georgia models.
2. Adopt a Revenue-Based “Small Business” Definition: Replace or supplement the $5 million net book value asset test with a revenue-based threshold (e.g., < $5 million in annual gross receipts) to ensure that high-capital-intensity startups are not penalized for their infrastructure investments.
3. Enhance Digital Administration and Oversight: Direct the Comptroller’s Office to fully integrate the payroll offset election into the “Maryland Tax Connect” portal, ensuring real-time accountability, ease of use for small business owners, and robust fraud detection.
4. Leverage Existing Administrative Precedents: Utilize the existing framework for non-profit withholding credits (Administrative Release No. 34) as a blueprint for rapid, low-cost implementation.

By bridging the liquidity gap for its most promising startups, Maryland can ensure that its high-tech ecosystem remains vibrant, its workforce remains at the global forefront of discovery, and its long-term economic future remains secure. The cost of this reform is manageable and capped, while the cost of inaction—measured in lost potential, exported intellectual property, and a stagnant startup corridor—is one the state cannot afford to pay.

Works Cited

1. Biotech and Life Sciences Update in Maryland, accessed March 22, 2026, https://pdab.maryland.gov/Documents/presentations/2025/MTC%20PDAB%20PPT%20%281%29.pdf
2. Department of Business and Economic Development (Prior Name of DOC) – Swanson Reed, accessed March 22, 2026, https://www.swansonreed.com/research-tax-credit/maryland/glossary/department-of-business-and-economic-development/
3. Do you qualify for the R&D credit payroll tax offset? – Wipfli, accessed March 22, 2026, https://www.wipfli.com/insights/articles/tax-eligibility-for-the-research-and-development-credit-payroll-tax-offset
4. Qualified Small Business (QSB) Payroll Tax Credit | United States – Leyton, accessed March 22, 2026, https://leyton.com/us/insights/articles/qualified-small-business-qsb-payroll-tax-credit/
5. R&D Payroll Tax Offset Guide 101: How Unprofitable Startups Can Secure Up to $500K in R&D Tax Credit – Chore, accessed March 22, 2026, https://www.hirechore.com/startups/r-d-payroll-tax-offset-guide
6. Research and Development Tax Credit (R&D) – Maryland Commerce, accessed March 22, 2026, https://commerce.maryland.gov/fund/programs-for-businesses/research-and-development-tax-credit
7. Maryland R&D Tax Credits – Get Info and Calculate R&D Tax Credits – Strike Tax Advisory, accessed March 22, 2026, https://www.striketax.com/state-rd-credits/maryland-r-d-tax-credits
8. 4 hour maryland tax law continuing professional education course, accessed March 22, 2026, https://gstti.com/courses/20184HourMaryland.pdf
9. Maryland Research and Development Tax Credit – Endeavor Advisors, accessed March 22, 2026, https://www.endeavoradvisors.com/maryland-rd-tax-credit/
10. Growth Credit Cap (Allocation Limit) Impact on R&D – Swanson Reed, accessed March 22, 2026, https://www.swansonreed.com/research-tax-credit/maryland/glossary/growth-credit-cap-allocation-limit/
11. MARYLAND Research and Development Tax Credits, accessed March 22, 2026, https://www.carolinebusiness.com/wp-content/uploads/2013/11/Maryland-RD-Tax-Credit-FAQs.pdf
12. Maryland Department of Commerce Fiscal 2021 Annual Report, accessed March 22, 2026, https://dlslibrary.state.md.us/publications/Exec/DC/commerce-annual-report-2021.pdf
13. Are R&D Tax Credits Available in Maryland? | See if You Qualify – KBKG, accessed March 22, 2026, https://www.kbkg.com/research-tax-credit/maryland-rd-tax-credit
14. 4 Hour Maryland Tax Law Continuing Professional Education Course, accessed March 22, 2026, https://gstti.com/courses/20214HourMaryland.pdf
15. State R&D Tax Credits for Biotech: The Hidden Opportunity Most Life Sciences Companies Miss – Boast, accessed March 22, 2026, https://www.boast.ai/en-us/blog/r-and-d/state-rd-tax-credits-for-biotech-the-hidden-opportunity-most-life-sciences-companies-miss
16. R&D Tax Credit: Federal vs. State Payroll Offset – Kruze Consulting, accessed March 22, 2026, https://kruzeconsulting.com/rd-tax-credit-federal-vs-state-payroll/
17. Maryland Form W-2 & MW508 Filing Requirements – TaxBandits, accessed March 22, 2026, https://www.taxbandits.com/w2-forms/maryland-state-filing-requirements/
18. R&D Tax Credits for Startups and Small Businesses – About BDO, accessed March 22, 2026, https://insights.bdo.com/R-D-Tax-Credits-for-Startups-and-Small-Businesses.html
19. payroll offsets using R&D tax credits (COVID-19) – KPMG agentic corporate services, accessed March 22, 2026, https://assets.kpmg.com/content/dam/kpmg/us/pdf/2020/03/20127.pdf
20. Research credit against payroll tax for small businesses | Internal Revenue Service, accessed March 22, 2026, https://www.irs.gov/credits-deductions/research-credit-against-payroll-tax-for-small-businesses
21. Research Tax Credit | Department of Revenue – Georgia.gov, accessed March 22, 2026, https://dor.georgia.gov/research-tax-credit
22. Georgia Tax Incentives | Georgia Department of Economic …, accessed March 22, 2026, https://georgia.org/competitive-advantages/incentives/tax-credits
23. Georgia Changes Process for Tax Credits for Some Companies – BDO, accessed March 22, 2026, https://www.bdo.com/insights/tax/georgia-changes-process-for-tax-credits-for-companies-performing-r-d-activities-in-the-state
24. Technology Business Tax Certificate Transfer (NOL) Program – Custom Portal, accessed March 22, 2026, https://programs.njeda.com/en-US/noltt_list/
25. Technology Business Tax Certificate Transfer (NOL) Program – NJEDA, accessed March 22, 2026, https://www.njeda.gov/nol/
26. New Jersey R&D Tax Credits – Strike Tax Advisory, accessed March 22, 2026, https://www.striketax.com/state-rd-credits/new-jersey-r-d-tax-credits
27. Maryland Income Tax – Administrative Release No. 34, accessed March 22, 2026, https://www.marylandcomptroller.gov/content/dam/mdcomp/tax/legal-publications/administrative-releases/income-and-estate-tax/ar_it34.pdf
28. Administrative Release No. 39 – Comptroller of Maryland, accessed March 22, 2026, https://www.marylandcomptroller.gov/content/dam/mdcomp/tax/legal-publications/administrative-releases/income-and-estate-tax/ar_it39.pdf
29. 2024 Employer Withholding Guide – Comptroller of Maryland, accessed March 22, 2026, https://www.marylandcomptroller.gov/content/dam/mdcomp/tax/instructions/2024/Withholding-Guide.pdf
30. 2024 Maryland Form MW508 Annual Employer Withholding Reconciliation Return, accessed March 22, 2026, https://www.marylandcomptroller.gov/content/dam/mdcomp/tax/forms/2024/MW508.pdf
31. Maryland 2024 Instructions for Filing Corporation Income Tax Returns – TaxFormFinder, accessed March 22, 2026, https://www.taxformfinder.org/forms/2024/2024-maryland-corporate-booklet.pdf
32. Comptroller of Maryland, accessed March 22, 2026, https://www.marylandcomptroller.gov/
33. Senate Budget and Taxation Committee February 3, 2026 Senate Bill 247 – Biotechnology Investment Incentive Tax Credit – Maryland, accessed March 22, 2026, https://mgaleg.maryland.gov/cmte_testimony/2026/bat/1XoKaqcqiYamLKmTZ_ulbtHyCbIqGsurK.pdf
34. AVOIDING TAX SCAMS | Comptroller of Maryland, accessed March 22, 2026, https://www.marylandcomptroller.gov/content/dam/mdcomp/md/tax-security/avoiding-tax-scams-factsheet.pdf
35. 2025 Form MD Comptroller MW508 Fill Online, Printable, Fillable, Blank – pdfFiller, accessed March 22, 2026, https://form-mw508.pdffiller.com/
36. Maryland Audits, accessed March 22, 2026, https://mvlslaw.org/wp-content/uploads/2019/12/Maryland-Audits.5-14-19-2.pdf
37. Business Tax Fraud Tips & Whistleblower Referral – Comptroller of Maryland, accessed March 22, 2026, https://www.marylandcomptroller.gov/businesses/business-tax-fraud-tips-whistleblower-referral.html
38. MEDA Study Shows Record ROI for Economic Development in MD Counties, accessed March 22, 2026, https://conduitstreet.mdcounties.org/2026/01/14/meda-study-shows-record-roi-for-economic-development-in-md-counties/
39. MEDA Study Shows Record Return on Investment for County Economic Development in Maryland, accessed March 22, 2026, https://www.medamd.com/public-policy-awareness/meda-study-shows-record-return-on-investment-for-county-economic-development-in-maryland/
40. US Biotech Job Market: 2025 Trends, Data & Analysis – IntuitionLabs, accessed March 22, 2026, https://intuitionlabs.ai/pdfs/us-biotech-job-market-2025-trends-data-analysis.pdf
41. 2024 Industry Snapshot – Massachusetts Biotechnology Council, accessed March 22, 2026, https://www.massbio.org/wp-content/uploads/2024/08/2024_IndustrySnapshot.pdf
42. A Quarter of US-Trained Scientists Eventually Leave. Is the US Giving Away Its Edge?, accessed March 22, 2026, https://arxiv.org/html/2512.11146v1
43. US Biotech Job Market: 2025 Trends, Data & Analysis – IntuitionLabs, accessed March 22, 2026, https://intuitionlabs.ai/articles/us-biotech-job-market-2025
44. Losing Our Minds: Brain Drain across the United States – Joint Economic Committee, accessed March 22, 2026, https://www.jec.senate.gov/public/index.cfm/republicans/2019/4/losing-our-minds-brain-drain-across-the-united-states
45. Report: Worcester not immune to life science headwinds, accessed March 22, 2026, https://wbjournal.com/article/report-worcester-not-immune-to-life-science-headwinds/